- 10% of devices entered market without premarket testing.
- Study assessed 1,041 therapeutic devices.
- 75 devices were authorized, 34 were high-risk.
- Mean review time was 225.8 days.
- 40% required postmarket studies.
Source: JAMA Internal Medicine
Breakthrough Device Approvals Outpacing Data
Conexiant
June 30, 2025
